Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

UCB Acquires Neurona Therapeutics for $1.15 Billion to Expand Epilepsy Portfolio – Regenerative Neural Cell Therapy NRTX-1001 Targets Drug-Refractory Epilepsy with Single-Dose GABA-Producing Cell Injection

Fineline Cube Apr 20, 2026
Company Deals

Pulnovo Medical Secures $100M+ Oversubscribed Financing Led by Medtronic – PADN System for Pulmonary Hypertension Attracts Global Investor Consortium

Fineline Cube Apr 20, 2026
Company Deals

SenseTime Raises $73.3 Million in Series A Financing for AI Healthcare Platform – Medical Agentic OS and World Model Capabilities Attract Raffles Healthcare, Lion Partners

Fineline Cube Apr 20, 2026
Company Deals

Mabwell Bioscience Raises $185 Million in Hong Kong IPO After Two Previous Failed Attempts – Oncology and Age-Related Disease Developer Secures HK$1.45 Billion Valuation

Fineline Cube Apr 20, 2026
Company Deals

Eli Lilly in Advanced Talks to Acquire Kelonia Therapeutics for Over $2 Billion – Strengthening CAR-T Cell Therapy Portfolio

Fineline Cube Apr 20, 2026
Policy / Regulatory

China’s NMPA Proposes New Quality Management Standards for Drug Retail Chains – Mandating Unified Systems Across Headquarters, Distribution Centers, and Stores

Fineline Cube Apr 20, 2026
Company Drug

LEO Pharma Secures NMPA Approval for Enstilar Foam in China – First and Only Calcipotriol/Betamethasone Foam Formulation for Plaque Psoriasis Demonstrates Superior Efficacy vs. Ointment

Fineline Cube Apr 20, 2026
Company Drug

Sino Biopharmaceutical’s Subsidiary Chia Tai Tianqing Secures NMPA Approval for Benmelstobart-Anlotinib Combo in Alveolar Soft Part Sarcoma – 72.4% ORR and Unreached Median PFS in Rare Cancer Indication

Fineline Cube Apr 20, 2026
Company Drug

Suzhou Abogen’s RSV mRNA Vaccine IND Approved by China’s CDE

Fineline Cube Mar 5, 2025

China-based nucleic acid drug developer Suzhou Abogen Biosciences announced that the Investigational New Drug (IND)...

Policy / Regulatory

CDE Launches SPARK Project to Boost Pediatric Antitumor Drug R&D

Fineline Cube Mar 5, 2025

China’s Center for Drug Evaluation (CDE) has released a notification to solicit feedback on its...

Company Drug

BeiGene’s Tevimbra Receives FDA Approval for ESCC Treatment

Fineline Cube Mar 5, 2025

BeiGene, Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), a multinational oncology company planning to change...

Company

Organon’s 2024 Financial Report Shows Steady Growth in Women’s Health and Biosimilars

Fineline Cube Mar 4, 2025

Women’s health specialist Organon (NYSE: OGN) released its 2024 financial report, showing a 3% year-on-year...

Company Drug

AstraZeneca and Daiichi Sankyo’s Enhertu Shows Positive Results in Phase III Study

Fineline Cube Mar 4, 2025

Partners AstraZeneca (NASDAQ: AZN) and Daiichi Sankyo (TYO: 4568) announced positive topline results from the...

Company

Boehringer Ingelheim Appeals CNIPA’s Invalidation of Jardiance Patents

Fineline Cube Mar 4, 2025

The Intellectual Property Court of the Supreme People’s Court of China issued a notice, holding...

Company Drug

Genentech’s TNKase Approved by FDA for Acute Ischemic Stroke Treatment

Fineline Cube Mar 4, 2025

Genentech, a subsidiary of Swiss giant Roche (SWX: ROG, OTCMKTS: RHHBY), announced that its thrombolytic...

Company Drug

Eisai’s Lecanemab Rejected by Australia’s TGA for Early Alzheimer’s Treatment

Fineline Cube Mar 4, 2025

Japan-based Eisai Co., Ltd (TYO: 4523) announced that the Therapeutic Goods Administration (TGA) of Australia...

Company Deals Medical Device

Boston Scientific to Acquire SoniVie, Boosting Hypertension Treatment Portfolio

Fineline Cube Mar 4, 2025

Boston Scientific Corporation (NYSE: BSX) is set to acquire SoniVie Ltd, an Israel-based medical device...

Company Drug

Fapon Biopharma’s FP008 Receives FDA Approval for Clinical Trials

Fineline Cube Mar 4, 2025

China-based Fapon Biopharma announced that it has received clinical trial approval from the US Food...

Company Deals

Kyorin Pharmaceutical Licenses KRP-M223 to Novartis for Global Development

Fineline Cube Mar 4, 2025

Japan-based Kyorin Pharmaceutical Co., Ltd. announced a licensing agreement with Novartis (NYSE: NVS), granting the...

Company Drug

GSK’s Depemokimab Accepted for FDA Review as Ultra-Long-Acting Biologic

Fineline Cube Mar 4, 2025

GSK plc (LON: GSK, NYSE: GSK) announced that the US Food and Drug Administration (FDA)...

Company Drug

Juvestar and Raziel Therapeutics Launch Phase III Study for RZL-012 in China

Fineline Cube Mar 4, 2025

Juvestar Biotech Co., Ltd., a subsidiary of China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA:...

Company Medical Device

Waters and Kehua’s LC-MS Systems Gain NMPA Approval for IVD Use

Fineline Cube Mar 4, 2025

Two home-grown liquid chromatography with tandem mass spectrometry (LC-MS) systems, the ACQUITY UPLC I-Class PLUS...

Company Drug

Zai Lab’s Augtyro Receives TFDA Approval for ROS1-Positive NSCLC and NTRK Fusion Solid Tumors

Fineline Cube Mar 4, 2025

China-based biotech Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) announced that it has received marketing...

Company Deals

Shanghai BioScience Completes RMB 100M Financing Round Led by HUAGAI Capital

Fineline Cube Mar 4, 2025

China-based Shanghai BioScience Co., Ltd., a life sciences service platform, announced the completion of a...

Company Deals Digital

Bayer HealthCare and JD Healthcare Partner on Women’s Health Ecosystem

Fineline Cube Mar 4, 2025

German pharmaceutical giant Bayer HealthCare (ETR: BAYN) has entered into a new partnership with JD...

Company Drug

Huadong Medicine’s HDM1005 Receives NMPA Approval for Clinical Trials

Fineline Cube Mar 4, 2025

China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that it has received clinical trial approval...

Company Medical Device

Bio-heart’s Iberis RDN System Completes First Commercial Surgery in Germany

Fineline Cube Mar 4, 2025

China-based Shanghai Bio-heart Biological Technology Co., Ltd (HKG: 2185) announced the successful completion of its...

Company Deals

Geneseeq and MGI Tech Form Global Partnership for Oncology Solutions

Fineline Cube Mar 4, 2025

Geneseeq Technology Inc., a genetic cancer testing service provider operating in Canada and China, has...

Posts pagination

1 … 190 191 192 … 654

Recent updates

  • LEO Pharma Secures NMPA Approval for Enstilar Foam in China – First and Only Calcipotriol/Betamethasone Foam Formulation for Plaque Psoriasis Demonstrates Superior Efficacy vs. Ointment
  • Sino Biopharmaceutical’s Subsidiary Chia Tai Tianqing Secures NMPA Approval for Benmelstobart-Anlotinib Combo in Alveolar Soft Part Sarcoma – 72.4% ORR and Unreached Median PFS in Rare Cancer Indication
  • UCB Acquires Neurona Therapeutics for $1.15 Billion to Expand Epilepsy Portfolio – Regenerative Neural Cell Therapy NRTX-1001 Targets Drug-Refractory Epilepsy with Single-Dose GABA-Producing Cell Injection
  • Hansoh Pharmaceutical Presents Promising Phase I Data for B7-H3 ADC Risvutatug Rezetecan Combined with Adebrelimab at AACR 2026 – 47.1% ORR and 14.0-Month PFS in Solid Tumors
  • Pulnovo Medical Secures $100M+ Oversubscribed Financing Led by Medtronic – PADN System for Pulmonary Hypertension Attracts Global Investor Consortium
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

LEO Pharma Secures NMPA Approval for Enstilar Foam in China – First and Only Calcipotriol/Betamethasone Foam Formulation for Plaque Psoriasis Demonstrates Superior Efficacy vs. Ointment

Company Drug

Sino Biopharmaceutical’s Subsidiary Chia Tai Tianqing Secures NMPA Approval for Benmelstobart-Anlotinib Combo in Alveolar Soft Part Sarcoma – 72.4% ORR and Unreached Median PFS in Rare Cancer Indication

Company Deals

UCB Acquires Neurona Therapeutics for $1.15 Billion to Expand Epilepsy Portfolio – Regenerative Neural Cell Therapy NRTX-1001 Targets Drug-Refractory Epilepsy with Single-Dose GABA-Producing Cell Injection

Company Drug

Hansoh Pharmaceutical Presents Promising Phase I Data for B7-H3 ADC Risvutatug Rezetecan Combined with Adebrelimab at AACR 2026 – 47.1% ORR and 14.0-Month PFS in Solid Tumors

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.